So, you're looking at your screen Monday morning and see Relmada Therapeutics (RLMD) shares up nearly 50% before the market even opens. What gives? It's the classic biotech one-two punch: promising clinical data and a fresh pile of cash.
The big news is coming from the company's ongoing Phase 2 trial for NDV-01, a treatment for non-muscle invasive bladder cancer. The 12-month interim data is turning heads. It showed a complete response rate of 76% overall, which is good. But it gets even more interesting when you look at specific patient groups. For patients who don't respond to the standard BCG therapy—a group with very limited options—the response rate was 80%.
But wait, there's more data from Monday itself. The trial is now showing a complete response rate of 95% at any time in high-risk patients, and 94% in that tough-to-treat BCG-unresponsive population. Numbers like that aren't just statistics; they're potential lifelines for patients. This is the kind of data that makes a drug candidate look like a serious contender and supports moving it into a Phase 3 registrational program, which Relmada plans to do with its RESCUE program.
There's another practical angle here that could really matter for adoption. NDV-01 is designed to be administered in less than five minutes without needing anesthesia. Think about that from a doctor's or clinic's perspective. A quick, in-office procedure is a lot easier to handle than something that requires an operating room. That convenience could be a major selling point if the drug gets approved.
The favorable safety profile and these high response rates suggest NDV-01 could become a leading option for a disease that desperately needs new treatments. But developing drugs is expensive, which brings us to the second part of Relmada's Monday announcement: money.
The company said it closed an oversubscribed private placement, raising approximately $160 million. They're selling about 29.5 million shares at $4.75 each and pre-funded warrants for another 4.2 million shares at $4.749 each. That's a serious war chest. For a clinical-stage biotech, this isn't just nice-to-have funding; it's the fuel needed to power the expensive Phase 3 trials and other work required to get a drug to market. It signals strong investor confidence, likely buoyed by the very data they just released.
Now, let's talk about the stock itself, because the move has been dramatic. Over the past year, Relmada has been on a tear. As of this news, the stock is trading 65.9% above its 20-day simple moving average and a whopping 87.2% above its 100-day average. That's what strong upward momentum looks like on a chart.
The Relative Strength Index (RSI) is sitting at 54.02, which is considered neutral—so the stock isn't in overbought or oversold territory just yet. Meanwhile, the Moving Average Convergence Divergence (MACD) indicator is at 0.1692, which is above its signal line of 0.1353. That's typically read as a bullish signal. Put together, you have a stock with neutral short-term momentum but underlying bullish indicators, suggesting there could be more room to run. Traders are watching key resistance at $6.00 and support at $5.00.
What are the pros saying? The analyst consensus is a Buy rating with an average price target of $26.54, which is miles above the current premarket price around $6.55. There's been notable activity recently: Lucid Capital Markets initiated coverage with a Buy rating and a $14 target on March 2. Leerink Partners upgraded the stock to Outperform with an $8 target back in January. Jefferies also started coverage with a Buy and a $9 target late last year.
In Monday's premarket action, Relmada shares were up 47.19% to $6.55, hitting a new 52-week high. It's a big move driven by two fundamental pillars for any biotech: compelling science that addresses a real need, and the capital to see that science through to the finish line. Investors are betting that Relmada now has both.
